Reduced streptolysin 0, with a potency of 2 International Unit equivalents per ml, purchased from Wellcome Reagents Ltd, was used in the Rantz and Randall method. The technique detailed in the instructions with the package was strictly adhered to. Each batch of tests were controlled by using an anti-streptolysin 0 also purchased from Wellcome Reagents Ltd.
SYNOPSIS This paper describes the modification of a commercially available rapid slide screening test1 for anti-streptolysin 0 to give quantitative results. The modified technique is compared with the long-established haemolytic technique of Rantz and Randall (1945) .
The quantitative results for both techniques are shown to be comparable. The modified slide test offers the advantage of saving time and labour.
Modified Rapid Slide Test
Sera submitted to this laboratory for anti-streptolysin O titres from 100 patients were analysed by the Rantz and Randall haemolytic technique, and our modification of the rapid slide screening test (Behringwerke).
Reduced streptolysin 0, with a potency of 2 International Unit equivalents per ml, purchased from Wellcome Reagents Ltd, was used in the Rantz and Randall method. The technique detailed in the instructions with the package was strictly adhered to. Each batch of tests were controlled by using an anti-streptolysin 0 also purchased from Wellcome Reagents Ltd.
The total incubation time for this method is one hour. The last dilution tube showing no haemolysis, indicating that the streptolysin 0 which has been added is neutralized by the anti-streptolysin 0 in the patient's serum, is taken as the end point.
The rapid slide screening test (Behringwerke Latex-ASL) was designed by the manufacturers as a qualitative screening test to detect those sera showing a significant increase in anti-streptolysin 0 (more than 200 iu/ml). In its original form, 0-1 ml of the test serum is incubated with 0 3 ml of the streptolysin 0 supplied at room temperature for 15 minutes.
One volume of this dilution is then mixed with 1 volume of a sensitized latex suspension on a glass slide, and examined for macroscopic agglutination after gentle rocking for approximately four to six minutes. Sera showing distinct agglutination are interpreted as having anti-streptolysin 0 levels of 200 iu per ml or more.
We have modified this method to provide a quantitative anti-streptolysin 0 titre. Further dilutions of the patient's serum may be made to determine the final titre in those sera showing strong agglutination with the dilution containing 600 iu per ml of streptolysin 0. In our experience only 15% of sera submitted for antistreptolysin 0 estimation have a titre exceeding 600 iu per ml.
In our experience the recommendation of the manufacturers of incubation at room temperature and a long mixing time made the slide test oversensitive. More Thirty-five sera had titres in the normal range up to 125 iu and 28 sera had significantly raised levels of anti-streptolysin 0, ranging from 333 to 1,250 iu per ml, by the Rantz and Randall method. The titre levels obtained by the modified slide test were similar in all cases in both these groups.
A further 37 sera had haemolytic titres in the 'borderline significant' range of 166 to 333 iu per ml of anti-streptolysin 0. In this group the titre result Rantz The modified slide test described is a valuable and reliable test, especially for those laboratories wishing to report anti-streptolysin 0 titres on the same day as the specimen is received, a service that is particularly welcomed by visiting clinicians.
